Imatinib mesylate treatment of nephrogenic systemic fibrosis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: To examine the effectiveness of imatinib mesylate in the treatment of nephrogenic systemic fibrosis (NSF). Methods: Two patients with stage 5 chronic kidney disease and NSF were treated with oral imatinib mesylate at a dosage of 400 mg/day. Skin thickening and tethering were assessed using the modified Rodnan skin thickness score (MRSS), and knee joint flexion contractures were measured with a goniometer. Results: Each patient displayed progressive reduction of skin thickening and tethering, with a steady decrease in the MRSS, following the initiation of imatinib mesylate treatment. The patient who had knee joint contractures achieved increased knee extension with passive range‐of‐motion exercises once his skin thickening and tethering had begun to decrease. Within weeks of stopping imatinib mesylate, the skin changes recurred in each patient. Recurrent skin thickening and tethering again improved in the patient who resumed taking imatinib mesylate for longer than 2 weeks. Skin biopsies performed both before and after initial dosing of that patient revealed less fibrosis and less staining for type I procollagen after imatinib mesylate treatment, but essentially unchanged tissue gadolinium content. Conclusion: Imatinib mesylate treatment decreases fibrosis and results in the relatively rapid and steady improvement of skin changes and knee joint contractures in patients with stage 5 chronic kidney disease and NSF, despite the persistence of gadolinium in the tissues. Because skin changes recurred after discontinuation of imatinib mesylate, the duration for which treatment may be required is undetermined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distler, J. H. W., Jüngel, A., Huber, L. C., Schulze‐Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22314 · Cited by 383
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
“…inhibitor imatinib mesylate (Gleevec), which inhibits signaling of PDGF receptor and vascular endothelial growth factor receptor, did not affect survival or lung function in patients with IPF 168 , ongoing trials are investigating its potential as a treatment for nephrogenic systemic fibrosis 169 .”
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
The Pathogenesis of Systemic Sclerosis
Katsumoto, T. R., Whitfield, M. L., & Connolly, M. K. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130312 · Cited by 313
Transforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295
Spiera, R. F., Gordon, J. K., Mersten, J. N., Magro, C. M., Mehta, M., Wildman, H. F., Kloiber, S., Kirou, K. A., Lyman, S., & Crow, M. K. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143974 · Cited by 173
Metadata
- Authors
- Kay, J., & High, W. A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-07-30
- Volume
- 58
- Issue
- 8
- Pages
- 2543-2548
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2074348974
- Cited by
- 150
- References
- 1
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.